GSK (LON:GSK) Issues Earnings Results

Key Points

• GSK reported a quarterly earnings per share (EPS) of GBX 75.30 ($1.01) with a return on equity of 18.08% and a net margin of 8.02%.
• Following the earnings announcement, GSK shares increased by 4.7%, reaching a price of GBX 1,462.50 ($19.53) with a market capitalization of £59.35 billion.
• Research analysts have varied ratings on GSK, with target prices ranging from GBX 1,450 ($19.36) to GBX 2,000 ($26.71) based on recent evaluations.

GSK (LON:GSK - Get Free Report) released its quarterly earnings results on Wednesday. The company reported GBX 75.30 ($1.00) earnings per share for the quarter, Digital Look Earnings reports. GSK had a return on equity of 18.08% and a net margin of 8.02%.

GSK Stock Down 1.5%

GSK stock traded down GBX 21.50 ($0.29) during mid-day trading on Friday, hitting GBX 1,396.50 ($18.54). The company had a trading volume of 8,559,338 shares, compared to its average volume of 13,407,056. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The stock's 50 day moving average price is GBX 1,434.66 and its two-hundred day moving average price is GBX 1,425.41. GSK has a 12 month low of GBX 1,242.50 ($16.49) and a 12 month high of GBX 1,678.68 ($22.28). The company has a market capitalization of £56.67 billion, a PE ratio of 22.56, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

Insiders Place Their Bets

In other news, insider Emma Walmsley sold 5,473 shares of the business's stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of GBX 1,449 ($19.23), for a total value of £79,303.77 ($105,261.18). Also, insider Jonathan Symonds acquired 1,350 shares of GSK stock in a transaction that occurred on Friday, June 20th. The shares were purchased at an average price of GBX 1,435 ($19.05) per share, with a total value of £19,372.50 ($25,713.43). Over the last three months, insiders have purchased 1,905 shares of company stock valued at $2,732,835. 1.61% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on GSK. Shore Capital restated a "buy" rating and set a GBX 2,000 ($26.55) price target on shares of GSK in a research report on Wednesday. JPMorgan Chase & Co. restated an "underweight" rating on shares of GSK in a research report on Friday, July 18th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a GBX 1,450 ($19.25) price target on shares of GSK in a research report on Thursday. Finally, Berenberg Bank restated a "hold" rating and set a GBX 1,600 ($21.24) price target on shares of GSK in a research report on Friday, July 18th.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.